Cargando…

Etoposide-based therapy for severe forms of COVID-19

The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between modera...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamizi, Kamel, Aouidane, Souhila, Belaaloui, Ghania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207128/
https://www.ncbi.nlm.nih.gov/pubmed/32416415
http://dx.doi.org/10.1016/j.mehy.2020.109826
_version_ 1783530544600973312
author Hamizi, Kamel
Aouidane, Souhila
Belaaloui, Ghania
author_facet Hamizi, Kamel
Aouidane, Souhila
Belaaloui, Ghania
author_sort Hamizi, Kamel
collection PubMed
description The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19.
format Online
Article
Text
id pubmed-7207128
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72071282020-05-11 Etoposide-based therapy for severe forms of COVID-19 Hamizi, Kamel Aouidane, Souhila Belaaloui, Ghania Med Hypotheses Article The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19. Elsevier Ltd. 2020-09 2020-05-08 /pmc/articles/PMC7207128/ /pubmed/32416415 http://dx.doi.org/10.1016/j.mehy.2020.109826 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hamizi, Kamel
Aouidane, Souhila
Belaaloui, Ghania
Etoposide-based therapy for severe forms of COVID-19
title Etoposide-based therapy for severe forms of COVID-19
title_full Etoposide-based therapy for severe forms of COVID-19
title_fullStr Etoposide-based therapy for severe forms of COVID-19
title_full_unstemmed Etoposide-based therapy for severe forms of COVID-19
title_short Etoposide-based therapy for severe forms of COVID-19
title_sort etoposide-based therapy for severe forms of covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207128/
https://www.ncbi.nlm.nih.gov/pubmed/32416415
http://dx.doi.org/10.1016/j.mehy.2020.109826
work_keys_str_mv AT hamizikamel etoposidebasedtherapyforsevereformsofcovid19
AT aouidanesouhila etoposidebasedtherapyforsevereformsofcovid19
AT belaalouighania etoposidebasedtherapyforsevereformsofcovid19